Navigation Links
VisionGate Reports Advances In Its Cell-CT(TM) Automated 3D Cell Analysis Platform At ASC 2012 Scientific Meeting
Date:11/6/2012

PHOENIX, Nov. 6, 2012 /PRNewswire/ -- VisionGate, Inc., today reported that it presented new data confirming that its breakthrough Cell-CT™ platform for the automated analysis of three dimensional (3D) images of cells can identify disease-associated features that are not visible using 2D cytology.  The data were presented this week by VisionGate founder and CEO Alan Nelson, PhD, at the 60th Annual Scientific Meeting of the American Society of Cytopathology.

The Cell-CT produces 3D volumetric computed reconstructions of individual cells in very high resolution, using advanced digital microscopy technology.  The high resolution afforded by the Cell-CT's 3D imaging is critical for automated machine recognition of cell abnormalities.  In his presentation, Dr. Nelson showed that certain disease-associated cell features that are not visible in 2D imaging emerge in the 3D images generated by the Cell-CT.  Unlike 2D imaging, the Cell-CT's 3D images enable comprehensive analysis of each individual cell, illuminating the morphological features and providing the analytical information needed for accurate disease detection.

"The Cell-CT platform has the potential to enable the non-invasive early detection of serious diseases such as lung cancer, while transforming the role of the cytologist," commented Dr. Nelson. "The Cell-CT system is now fully automated, and we are on track to achieve imaging speeds of one cell per second, which makes high throughput automated screening feasible for cancer and other conditions."

In clinical applications, the Cell-CT can generate high-resolution 3D biosignatures from cells contained in patient samples such as sputum or blood, which may contain cancer cells that can be detected early in the disease process.  The biosignatures discovered in the 3D high resolution images may allow the Cell-CT to identify abnormal cells before symptoms appear.  In screening applications, advantages over current technology are expected to include lower cost per evaluation, no radiation exposure, higher specificity (low false-positive rate) with fewer unnecessary follow-up procedures, and the ability to automate and standardize the diagnostic procedure, which is essential for widespread disease prediction and early detection to become a reality. 

Dr. Nelson added, "One of the most exciting aspects of the Cell-CT platform is its potential for empowering cytologists with 21st century technology.  Once cell analysis is automated in a highly accurate and informative way and is internet-based, cytologists will be freed-up to apply their unique expertise to deliver definitive diagnoses either on-site or from remote locations anywhere in the world.  We believe the Cell-CT is widely applicable to cellular analysis, and we are working with the cytology community to ensure that the system addresses important unmet needs for the cost-effective management of patient health risks and disease."

"Three-Dimensional Cellular Morphometry: A New Horizon for Cytology and Cancer Detection," was presented by Dr. Nelson on November 4, 2012 at the American Society of Cytopathology's 60th Annual Scientific Meeting.  For more information, visit http://cytopathologymeeting.org/2012/.

About VisionGate
VisionGate, Inc. is creating the standard of care for diagnostic cell analysis worldwide, while developing a revolutionary non-invasive test for the early detection of lung cancer, using its automated 3D cell imaging platform, the Cell-CT™. The Cell-CT generates high-resolution 3D biosignatures from intact cells using a sputum or blood sample.  For more information, visit www.visiongate3D.com.

VisionGate
Scarlett Spring
President
602 617-1237
spring@visiongate3d.com 

Media
BLL Partners, LLC
Barbara Lindheim
212 584-2276
blindheim@bllbiopartners.com


'/>"/>
SOURCE VisionGate, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. VisionGate Uses $2.6 Million NIH Grant to Achieve Full Automation of Cell-CTâ„¢ 3D Imaging System for Early Diagnosis of Cancer
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Calif. , June 23, 2016  Blueprint Bio, ... biological discoveries to the medical community, has closed its ... Matthew Nunez . "We have received ... with the capital we need to meet our current ... essentially provide us the runway to complete validation on ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free ... and will showcase its product’s latest features from June 26 to June 30, ... poster on Disrupting Clinical Trials in The Cloud during the conference. DIA ...
(Date:6/23/2016)... FRANCISCO , June 22, 2016  Amgen (NASDAQ: ... sponsorship of the QB3@953 life sciences incubator ... human health. The shared laboratory space at QB3@953 was ... overcome a key obstacle for many early stage organizations ... part of the sponsorship, Amgen launched two "Amgen Golden ...
(Date:6/22/2016)... , June 22, 2016 Research and ... Global Markets" report to their offering. ... billion in 2014 from $29.3 billion in 2013. The market is ... of 13.8% from 2015 to 2020, increasing from $50.6 billion in ... projected product forecasts during the forecast period (2015 to 2020) are ...
Breaking Biology Technology:
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
Breaking Biology News(10 mins):